Neuraly Inc.

About

Neuraly Inc. is a clinical-stage biotechnology company based in Germantown, Maryland. It specializes in developing innovative neurotherapies for neurodegenerative diseases, particularly Parkinson's disease and Alzheimer's disease. As a subsidiary of D&D Pharmatech, Neuraly utilizes its expertise in glia biology to create a diverse product portfolio aimed at addressing these conditions. The company's lead asset, NLY01, is a microglia-targeted GLP-1R agonist currently in Phase 2 clinical trials for early Parkinson's and Alzheimer's patients. Neuraly is also advancing other candidates and pipeline assets, including drugs for obesity and stroke. With a commitment to translating scientific discoveries into effective treatments, Neuraly operates with a focus on integrity and collaboration, striving to improve the lives of those affected by neurodegenerative diseases.